Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CC-99282 + obinutuzumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
CC-99282 + obinutuzumab is a combination investigational therapy being studied for the treatment of hematologic malignancies, specifically relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and B-cell non-Hodgkin lymphoma. CC-99282 is a novel, orally administered cereblon E3 ligase modulator (CELMoD) that induces the targeted degradation of Ikaros and Aiolos, transcription factors implicated in B-cell malignancy biology. Obinutuzumab is a humanized type II monoclonal antibody directed against CD20, a surface antigen found on B lymphocytes, leading to B-cell depletion through antibody-dependent cellular cytotoxicity, phagocytosis, and direct cell death. The combination is being evaluated primarily for enhanced anti-tumor activity by combining B-cell targeting (obinutuzumab) with immune modulation and direct cytotoxic activity (CC-99282)[1][5][7][9].
- Brand names
- Gazyva
- Other names
- obinutuzumab
02
Targets
IKZF1 (Ikaros family zinc finger protein 1)CRBN (Cereblon)IKZF3 (Zinc finger protein Aiolos)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on CC-99282 + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CC-99282 + obinutuzumab.